DPAM
NBIX icon

Degroof Petercam Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Degroof Petercam Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$359K Hold
2,600
– – ﹤0.01% 537
2023
Q4 		$343K Buy
+2,600
New +$299K ﹤0.01% 535

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Degroof Petercam Asset Management's NBIX Position: Q1 2024 in Review

Degroof Petercam Asset Management held its Neurocrine Biosciences (NBIX) position steady in Q1 2024 at 2,600 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #537.

Degroof Petercam Asset Management first reported a position in NBIX in Q4 2023 and has held it in 2 quarters since. 590 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Degroof Petercam Asset Management held 2,600 shares of Neurocrine Biosciences worth $359K as of Q1 2024.
  • Degroof Petercam Asset Management left its Neurocrine Biosciences share count unchanged in Q1 2024.
  • Neurocrine Biosciences made up ﹤0.01% of Degroof Petercam Asset Management's portfolio in Q1 2024, its #537 holding.
  • Degroof Petercam Asset Management first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 2 quarters since.
  • 590 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Degroof Petercam Asset Management's 13F filing for Q1 2024, filed 13 May 2024.